These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 16323105

  • 1. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.
    Schewe CK, Maserati R, Wassmer G, Adam A, Weitner L.
    Clin Infect Dis; 2006 Jan 01; 42(1):145-7. PubMed ID: 16323105
    [Abstract] [Full Text] [Related]

  • 2. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.
    Antivir Ther; 2007 Jan 01; 12(3):407-15. PubMed ID: 17591031
    [Abstract] [Full Text] [Related]

  • 3. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
    Llibre JM, Domingo P, Palacios R, Santos J, Pérez-Elías MJ, Sánchez-de la Rosa R, Miralles C, Antela A, Moreno S, Lipo-Rec Study Group.
    AIDS; 2006 Jun 26; 20(10):1407-14. PubMed ID: 16791015
    [Abstract] [Full Text] [Related]

  • 4. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R, Nasi M, Di Biagio A, Repetto E, Dentone C, Pinti M, Nemes E, Ferraresi R, Mussini C, Esposito R, Viscoli C, Cossarizza A.
    Pediatr Infect Dis J; 2008 Jan 26; 27(1):17-21. PubMed ID: 18162932
    [Abstract] [Full Text] [Related]

  • 5. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.
    Antivir Ther; 2006 Jan 26; 11(2):233-43. PubMed ID: 16640104
    [Abstract] [Full Text] [Related]

  • 6. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G, Italian MASTER Cohort.
    J Antimicrob Chemother; 2007 Jun 26; 59(6):1141-7. PubMed ID: 17434879
    [Abstract] [Full Text] [Related]

  • 7. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
    Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G, Study 903 Team.
    Nephrol Dial Transplant; 2005 Apr 26; 20(4):743-6. PubMed ID: 15741212
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
    Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET.
    Ann Pharmacother; 2008 Nov 26; 42(11):1581-5. PubMed ID: 18957630
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
    Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J.
    J Infect; 2006 May 26; 52(5):335-8. PubMed ID: 16176835
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tenofovir: what have over 1 million years of patient experience taught us?
    Pozniak A.
    Int J Clin Pract; 2008 Aug 26; 62(8):1285-93. PubMed ID: 18705824
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S, Ghosn J, Peytavin G, Izzedine H, Wirden M, Ktorza N, Miller M, Aubron-Olivier C, Trylesinski A, Calvez V, Deray G, Katlama C.
    J Med Virol; 2007 Feb 26; 79(2):105-10. PubMed ID: 17177308
    [Abstract] [Full Text] [Related]

  • 16. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 26; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV, Cooper DA, Dore GJ.
    Antivir Ther; 2007 Mar 26; 12(1):119-22. PubMed ID: 17503756
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.